Sir Richard Thompson, the former president of the Royal College of Physicians and the Queen of England’s doctor for 21 years, was quoted in The Daily Express as saying,
    “The statin data needs to be urgently scrutinised.
    “We are very worried about it and particularly side-effect data which seems to have been swept under the carpet.
    “We have to be very wary of the doubts about statins produced by this new research and if we are wrong about widespread prescribing of this drug we have to stand up and say sorry.”

His quote was in response to the review paper by Michel de Lorgeril, MD, a cardiologist at the University of Grenoble in France, and Mikael Rabaeus, MD, a Swiss cardiologist, of statin studies done since 2005-2006, when rules changed making the results more credible.

Findings from their review paper are posted here.

Their report concluded “statins are not effective for cardiovascular prevention”.

Dr. De Lorgeril, was quoted as saying, “We cannot trust these trials. I would warn people not to take statins.”

“In conclusion, this review strongly suggests that statins are not effective for cardiovascular prevention,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

“The [statin] studies published before 2005/2006 were probably flawed, and this concerned in particular the safety issue,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

“A complete reassessment [of all statin trials] is mandatory.

“Until then, physicians should be aware that the present claims about the efficacy and safety of statins are not evidence based.”

“Our systematic review [of four (4) randomized controlled trials published since 2005/2006] ... unambiguously showed that rosuvastatin [Crestor] is not effective in secondary prevention, while the results are highly debatable in primary prevention,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

In other words, statins don’t work even in people who have had a heart attack!

Secondary prevention is when they give a drug—a statin in this case—to people who have had a heart attack or have cardiovascular disease and they are trying to prevent another heart attack or death.

Primary Prevention is when they give a drug—a statin in this case—to people who do not have cardiovascular disease or have not had a heart attack and are trying to prevent a heart attack or death in the first place.

“We then examined the most recent [randomized controlled trials] comparing statins to each other: all showed that no statin is more effective than any other, including rosuvastatin [Crestor],” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

In other words, all statins are equally ineffective at preventing heart attack and death!

“Furthermore, recent [randomized controlled trials] clearly indicate that intense cholesterol-lowering (including those with statins) does not protect high-risk patients any better than less-intense statin regimens,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

”[S]tatins appear ineffective in chronic heart failure and chronic kidney failure patients,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

“[S]tatins do not appear to protect diabetics [from an increased risk of heart attack and death],” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

“As for the safety of statin treatment – a major issue for medical doctors – it is quite worrisome to realize that it took 30 years to bring to light the triggering effect of statins on new-onset diabetes, manifestly reflecting a high level of bias in reporting harmful outcomes in commercial trials, as has been admitted by the recent confession of prominent experts in statin treatment,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.

Obviously, the drug companies hid this information and their paid researchers went along with this lie.

Can you understand why I don’t believe anything from the drug companies or from their paid researchers?